GEN Exclusives

More »

GEN News Highlights

More »
Nov 26, 2008

Sosei Out-Licenses Malaria IP to Treague

  • Sosei Group has out-licensed its IP relating to the RS(+) isomer of mefloquine to Treague, for the treatment and prophylaxis of malaria.

    Mefloquine is a antimalarial drug that is approved in its racemic form for both treatment (in combination with artesunate) and prophylaxis (as monotherapy) of malaria. Though its efficacy and long half-life make racemic mefloquine a particularly attractive antimalarial drug, its clinical utility has been compromised by CNS side effects, according to the companies. They believe, based on the stereoselective nature of mefloquine's receptor binding, that RS(+) mefloquine has the potential for substantially reduced CNS side effect liability.

    Treague is collaborating with Medicines for Malaria Venture, a Geneva-based not-for-profit organization dedicated to reducing the burden of malaria, to develop RS(+) mefloquine for the treatment of malaria in malaria endemic countries.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Tackling Climate Change

Do you think most companies will respond positively to the People’s Climate March?